摘要
背景:全球肺癌发病率呈上升趋势。主要危险因素是烟草暴露量增加,被动吸烟,蔬菜和水果消耗减少以及职业接触石棉,砷和铬。肺癌的病理生理学是复杂的,不是很清楚。各种微RNA,基因和通路与肺癌有关。涉及肺癌的基因产生涉及细胞生长,分化,不同细胞周期,凋亡,免疫调节,肿瘤扩散和进展的蛋白质。河马途径(也被称为Salvador-Warts-Hippo途径)是癌症中最新出现的概念。 Hippo途径通过其对细胞增殖和凋亡的作用在控制组织和器官的大小方面起着重要的作用。 目的:在本文中,我们重点介绍了哺乳动物Hippo通路,其核心成员,上游调节因子,下游效应物和肺癌耐药情况。 结果:Mer与细胞表面乙酰透明质酸受体CD44的特异性相互作用在细胞接触抑制中是至关重要的,从而激活Hippo通路。转录辅激活物YAP和TAZ(也称为WWTR1,是果蝇Yki的同系物)是增殖和凋亡的重要调节剂,并且作为Hippo途径的主要下游效应物。 Hippo通路上游调节因子NF2的突变与癌症有关。 结论:靶向YAP和TAZ可能对未来的药物输送和治疗非常重要
关键词: 细胞增殖,凋亡,河马途径,肺癌,基因,药物输送
图形摘要
Current Drug Targets
Title:The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications
Volume: 18 Issue: 16
关键词: 细胞增殖,凋亡,河马途径,肺癌,基因,药物输送
摘要: Background: The incidence of lung cancers has increased globally. Increased exposure to tobacco, passive smoking, less consumption of vegetables and fruits and occupational exposure to asbestos, arsenic and chromium are the main risk factors. The pathophysiology of lung cancer is complex and not well understood. Various microRNAs, genes and pathways are associated with lung cancers. The genes involved in lung cancers produce proteins involved in cell growth, differentiation, different cell cycles, apoptosis, immune modulation, tumor spread and progression. The Hippo pathway (also known as the Salvador-Warts-Hippo pathway) is the latest emerging concept in cancers. The Hippo pathway plays an important role in controlling the size of the tissue and organ by virtue of its action on cell proliferation and apoptosis.
Objective: In the present review, we highlight the mammalian Hippo pathway, role of its core members, its upstream regulators, downstream effectors and the resistance cases in lung cancers.
Results: Specific interaction of Mer with cell surface hyaluronan receptor CD44 is vital in cell contact inhibition, thereby activating Hippo pathway. Both transcription co-activators YAP and TAZ (also known as WWTR1, being homologs of Drosophila Yki) are important regulators of proliferation and apoptosis, and serve as major downstream effectors of the Hippo pathway. Mutation of NF2, the upstream regulator of Hippo pathway is linked to the cancers.
Conclusion: Targeting YAP and TAZ may be important for future drug delivery and treatment.
Export Options
About this article
Cite this article as:
The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications, Current Drug Targets 2017; 18 (16) . https://dx.doi.org/10.2174/1389450117666160907153338
DOI https://dx.doi.org/10.2174/1389450117666160907153338 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews CXC Chemokines in Angiogenesis Relevant to Chronic Fibroproliferation
Current Drug Targets - Inflammation & Allergy Molecular Mechanism of Deguelin in Anti-tumor Effect
Current Pharmaceutical Analysis MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design Targeting Transcription: A New Concept of Anti-Inflammatory Therapy of Airway Diseases
Current Drug Targets Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Current Immunology Reviews (Discontinued) Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Synthesis of Nitroaromatic Compounds as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics